Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-06-06
2006-06-06
Prouty, Rebecca E. (Department: 1652)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S094500, C435S194000, C530S300000, C530S350000, C530S324000, C530S325000, C530S326000
Reexamination Certificate
active
07056513
ABSTRACT:
The present invention is directed to novel telomerase nucleic acids and amino acids. In particular, the present invention is directed to nucleic acid and amino acid sequences encoding various telomerase protein subunits and motifs, including the 123 kDa and 43 kDa telomerase protein subunits ofEuplotes aediculatus, and related sequences fromSchizosaccharomyces, Saccharomycessequences, and human telomerase. The present invention is also directed to polypeptides comprising these telomerase protein subunits, as well as functional polypeptides and ribonucleoproteins that contain these subunits.
REFERENCES:
patent: 3817837 (1974-06-01), Tanenholtz et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3939350 (1976-02-01), Kronick et al.
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4275149 (1981-06-01), Litman et al.
patent: 4277437 (1981-07-01), Maggio
patent: 4366241 (1982-12-01), Tom et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5489508 (1996-02-01), West et al.
patent: 5583016 (1996-12-01), Villeponteau et al.
patent: 5597697 (1997-01-01), Diamond
patent: 5747317 (1998-05-01), Cao
patent: 5770422 (1998-06-01), Collins
patent: 5917025 (1999-06-01), Collins
patent: 5919656 (1999-07-01), Harrington et al.
patent: 6093809 (2000-07-01), Cech et al.
patent: 6166178 (2000-12-01), Cech et al.
patent: 6258535 (2001-07-01), Villeponteau et al.
patent: 6261556 (2001-07-01), Weinrich et al.
patent: 6261836 (2001-07-01), Cech et al.
patent: 6309867 (2001-10-01), Cech et al.
patent: 6337200 (2002-01-01), Morin
patent: 6440735 (2002-08-01), Gaeta
patent: 6444650 (2002-09-01), Cech et al.
patent: 6475789 (2002-11-01), Cech et al.
patent: 6517834 (2003-02-01), Weinrich et al.
patent: 6608188 (2003-08-01), Tsuchiya et al.
patent: 6610839 (2003-08-01), Morin et al.
patent: 6617110 (2003-09-01), Cech et al.
patent: 6627619 (2003-09-01), Cech et al.
patent: 2002/0187471 (2002-12-01), Cech et al.
patent: 2003/0009019 (2003-01-01), Cech et al.
patent: 2003/0032075 (2003-02-01), Cech et al.
patent: 2003/0044953 (2003-03-01), Cech et al.
patent: 2003/0059787 (2003-03-01), Cech et al.
patent: 2003/0096344 (2003-05-01), Cech et al.
patent: 2003/0100093 (2003-05-01), Cech et al.
patent: 2271718 (1998-05-01), None
patent: 2 317 891 (1998-04-01), None
patent: 09154575 (1997-06-01), None
patent: WO 84/03564 (1984-09-01), None
patent: WO 93/23572 (1993-11-01), None
patent: WO 94/17210 (1994-08-01), None
patent: WO 95/13382 (1995-05-01), None
patent: WO 96/01835 (1996-01-01), None
patent: WO 96/12811 (1996-05-01), None
patent: WO 96/19580 (1996-06-01), None
patent: WO 96/40868 (1996-12-01), None
patent: WO 98/01542 (1998-01-01), None
patent: WO 98/01543 (1998-01-01), None
patent: WO 98/08938 (1998-02-01), None
patent: WO 98/07838 (1998-03-01), None
patent: WO 98/14592 (1998-04-01), None
patent: WO 98/14593 (1998-04-01), None
patent: WO 98/21343 (1998-05-01), None
patent: WO 98/23759 (1998-06-01), None
patent: WO 98/37181 (1998-08-01), None
patent: WO 98/45450 (1998-10-01), None
patent: WO98/59040 (1998-12-01), None
patent: WO99/01560 (1999-01-01), None
patent: WO 99/33998 (1999-07-01), None
patent: WO 99/38964 (1999-08-01), None
patent: WO 00/46355 (2000-08-01), None
Adamson, D. et al. “Significant Telomere Shortening in Childhood Leukemia”, Cancer Genet. Cytogenet, 1992; pp. 204-206, vol. 61.
Chiu, et al. “Replicative senescence and cell immortality: the role of telomeres and telomerase (44075)”,Proc. Soc. Exp. Bio. Med., 1997, pp. 99-106, vol. 214.
Chong, L. et al. “A Human Telomeric Protein”,Science, Dec. 1995, pp. 1663-1667, vol. 270.
Counter, C. et al. “Telomerase activity in human ovarian carcinoma”;Proc. Natl. Acad. Sci USA; Apr. 1994; vol. 91; pp. 2900-2904.
Counter, C. et al. “Telomerase Activity in Normal Leukocytes and in Hematologic Malignancies”Blood; May 1, 1995; pp. 2315-2320, vol. 85, No. 9.
Counter, C. et al. “Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity”,The EMBO Journal; 1992, pp. 1921-1929, vol. 11; No. 5, Oxford University Press.
De Lange, T. et al. “Structure and Variability of Human Chromosome Ends”;Molecular and Cellular Biology; Feb. 1990; pp. 518-527, vol. 10, No. 2.
Flavell, R. & Mathias, R. “Prospects for transforming monocot crop plants”,Nature, Jan. 12, 1984, pp. 108-109, vol. 307.
Freshney,Culture of Animal Cells, A Manual Basic Technique, p. 4, Alan R. Liss, Inc. New York, 1983.
Genbank Accession No. A46242; Sep. 21, 1993.
Genbank Accession No. L38903; Jan. 30, 1995.
Genbank Accession No. Q06163; Nov. 01, 1995.
Genbank Accession No. S39696; Oct. 07, 1994.
Genbank Accession No. S53396; May 5, 1995.
GenBank Accession No. U95964; May 5, 1997.
Glaser, P. et al. “Bacillus subtilisgenome project: cloning and sequencing of the 97 kb region from 325 to 333 ”Molecular Microbiology, 1993, pp. 371-384, vol. 10, No. 2.
Goodman, R. et al. “Gene Transfer in Crop Improvement”, Science, Apr. 3 1997, pp. 48-54, vol. 236.
Greider, C. “Telomeres, Teleomerase and Senescence”;BioEssays; 1990; pp. 363-369, vol. 12, No. 8.
Harley, C. “Teleomere loss: Mitotic clock or genetic time bomb?”Mutation Research; 1991; pp. 271-282, vol. 256, Elsevier Science Publishers.
Harley, C. & Villeponteau, B. “Telomeres and telomerase in aging and cancer”Current Opinion in Genetics and Development; 1995, pp. 249-255, vol. 5.
Harley, C. et al. “Telomeres shorten during ageing of human fibroblasts”,Nature, May 31 1990; pp. 458-460, vol. 345.
Hastie, N. et al. “Telomere reduction in human colorectal carcinoma and with ageing”,Nature, Aug. 30 1990, pp. 866-868, vol. 346.
Healy, K. C. “Telomere dynamics and telomerase activation in tumor progression: prospects for prognosis and therapy”Oncol. Res., 1995, pp. 121-130, vol. 7.
Henderson, C. Cancer genetics gene regulates telomerase resulting in death of cancer cells;Gene Therapy Weekly; Sep. 11 1995.
Hiyama, E. et al. “Correlating telomerase activity levels with human neuroblastoma cutcomes”;Nature Medicine; Mar. 3 1995; pp. 249-255, vol. 1, No. 3.
Holtzmann, K. et al. “Telomeric Associations and Loss of Telomeric DNA Repeats in Renal Tumors”,Genes, Chromosomes&Cancer, 1993, pp. 178-181, vol. 6.
Jähne, A. et al. “Genetic Engineering of Cereal Crop Plants: A Review”, Euphytica, 1995, pp. 35-44, vol. 85, Kluwer Academic Publishers, Netherlands.
Johnson, P. et al., “Expression of Wild-Type p53 Is Not Compatible with Continued Growth of p53-Negative Tumor Cells”,Molecular and Cellular Biology, Jan. 1991, p. 1-11, vol. 11, No. 1.
Jolliffe, L.K. “Humanized antibodies: enhancing therapeutic utility through antibody engineering”,int. Rev. Immunol., 1993, pp. 241-250, vol. 10.
Kim, N. et al. “Specific Association of Human Telomerase Activity with Immortal Cells and Cancer”,Science, Dec. 23 1994, pp. 2011-2014, vol. 266.
Klinglhutz, A. et al. “Restoration of Telomerase in Human Papillomavirus-Immortalized Human Anogenital Epithelial Cells”;Molecular and Cellular Biology; Feb. 1994, pp. 961-969, vol. 14, No. 2.
Lewis, A. & Crowe, J.S. “Generation of humanized monoclonal antibodies by ‘best fit’ framework selection and recombinant polymerase chain reaction”,Year Immunol., 1993, pp. 110-118, vol. 7.
Linking telomerase and tumors;Genesis Report—Dx; 1995; vol. 4, No. 6; Publisher Genesis Group Associates.
Malicki, J. et al. “A human HOX4B regulatory element provides head-specific expression in Drosophila embryos”, Nature, Jul. 23 1992, pp. 345-357, vol. 358.
Natarajan et al. “Major histocompatibility complex determinants select T-cell receptor alpha chain variable region
Andrews William H.
Cech Thomas R.
Chapman Karen B.
Harley Calvin B.
Lingner Joachim
Ausenhus Scott L.
Geron Corporation
Prouty Rebecca E.
Regents of the University of Colorado
Schiff J. Michael
LandOfFree
Telomerase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Telomerase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Telomerase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3649743